Farzaneh Forouz

Dr Farzaneh Forouz is a Postdoctoral Research Fellow at the School of Pharmacy and Pharmaceutical Sciences, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland (UQ), specializing in cancer biology and pharmaceutical sciences with emphasis on breast cancer and melanoma therapeutics. She holds a PhD in Medical Science from UQ and is available for research student supervision.

Education:

• Doctor of Philosophy of Science in Medical Science, The University of Queensland

Research Interests:

Her work spans cancer genomics, drug delivery platform development, and molecular signaling mechanisms. Key focus areas include genomic instability in breast cancer (copy number alterations, chromosome aneuploidies), hydrogel-based 3D drug testing systems for patient-derived organoids, topical/transdermal delivery optimization using liposomes and microemulsions, and calcium signaling dynamics in tumor microenvironments. She investigates excipient toxicity in epithelial models and anti-melanoma properties of novel formulations.

Publication Trends:

Her 2020-2024 publications demonstrate consistent contributions to breast cancer genomics and advanced drug delivery. Major themes include genomic catastrophe orchestration in breast cancer (Trends in Molecular Medicine 2024), bioprinted hydrogels for ex vivo drug testing (Pharmaceutics 2023), and calcium signaling's role in cancer progression. Recent conference work explores intermittent BRAF inhibitor exposure in melanoma and ORAI1-mediated cytokine expression.

Scientific Awards:

• No scientific awards listed in available information

Supervision and Collaborations:

Available for research student supervision with active collaborations across UQ's cancer research ecosystem, particularly with the Monteith group (calcium signaling in breast cancer) and Grice/Roberts teams (drug delivery and skin penetration). No specific grant details provided.

Research Environment:

Operates within interdisciplinary teams at UQ developing translational cancer therapeutics, with emphasis on bridging molecular oncology and pharmaceutical formulation science through organoid models and microenvironment studies.